Tom G Jacobs1, Elin M Svensson1,2, Victor Musiime3,4, Pablo Rojo5, Kelly E Dooley6, Helen McIlleron7, Rob E Aarnoutse1, David M Burger1, Anna Turkova8, Angela Colbers1. 1. Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands. 2. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. 3. Research Department, Joint Clinical Research Centre, Kampala, Uganda. 4. Department of Paediatrics and Child Health, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. 5. Pediatric Infectious Diseases Unit. Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense, Madrid, Spain. 6. Divisions of Clinical Pharmacology and Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 8. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Abstract
INTRODUCTION: Management of concomitant use of ART and TB drugs is difficult because of the many drug-drug interactions (DDIs) between the medications. This systematic review provides an overview of the current state of knowledge about the pharmacokinetics (PK) of ART and TB treatment in children with HIV/TB co-infection, and identifies knowledge gaps. METHODS: We searched Embase and PubMed, and systematically searched abstract books of relevant conferences, following PRISMA guidelines. Studies not reporting PK parameters, investigating medicines that are not available any longer or not including children with HIV/TB co-infection were excluded. All studies were assessed for quality. RESULTS: In total, 47 studies met the inclusion criteria. No dose adjustments are necessary for efavirenz during concomitant first-line TB treatment use, but intersubject PK variability was high, especially in children <3 years of age. Super-boosted lopinavir/ritonavir (ratio 1:1) resulted in adequate lopinavir trough concentrations during rifampicin co-administration. Double-dosed raltegravir can be given with rifampicin in children >4 weeks old as well as twice-daily dolutegravir (instead of once daily) in children older than 6 years. Exposure to some TB drugs (ethambutol and rifampicin) was reduced in the setting of HIV infection, regardless of ART use. Only limited PK data of second-line TB drugs with ART in children who are HIV infected have been published. CONCLUSIONS: Whereas integrase inhibitors seem favourable in older children, there are limited options for ART in young children (<3 years) receiving rifampicin-based TB therapy. The PK of TB drugs in HIV-infected children warrants further research.
INTRODUCTION: Management of concomitant use of ART and TB drugs is difficult because of the many drug-drug interactions (DDIs) between the medications. This systematic review provides an overview of the current state of knowledge about the pharmacokinetics (PK) of ART and TB treatment in children with HIV/TB co-infection, and identifies knowledge gaps. METHODS: We searched Embase and PubMed, and systematically searched abstract books of relevant conferences, following PRISMA guidelines. Studies not reporting PK parameters, investigating medicines that are not available any longer or not including children with HIV/TB co-infection were excluded. All studies were assessed for quality. RESULTS: In total, 47 studies met the inclusion criteria. No dose adjustments are necessary for efavirenz during concomitant first-line TB treatment use, but intersubject PK variability was high, especially in children <3 years of age. Super-boosted lopinavir/ritonavir (ratio 1:1) resulted in adequate lopinavir trough concentrations during rifampicin co-administration. Double-dosed raltegravir can be given with rifampicin in children >4 weeks old as well as twice-daily dolutegravir (instead of once daily) in children older than 6 years. Exposure to some TB drugs (ethambutol and rifampicin) was reduced in the setting of HIV infection, regardless of ART use. Only limited PK data of second-line TB drugs with ART in children who are HIV infected have been published. CONCLUSIONS: Whereas integrase inhibitors seem favourable in older children, there are limited options for ART in young children (<3 years) receiving rifampicin-based TB therapy. The PK of TB drugs in HIV-infectedchildren warrants further research.
Authors: Kendra K Radtke; Kelly E Dooley; Peter J Dodd; Anthony J Garcia-Prats; Lindsay McKenna; Anneke C Hesseling; Radojka M Savic Journal: Lancet Child Adolesc Health Date: 2019-07-16
Authors: Helen McIlleron; Marianne Willemse; Cedric J Werely; Gregory D Hussey; H Simon Schaaf; Peter J Smith; Peter R Donald Journal: Clin Infect Dis Date: 2009-06-01 Impact factor: 9.079
Authors: Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Emmanuel Chigutsa; Sandra Meredith; Lubbe Wiesner; Nesri Padayatchi; Joe Harding; Prashini Moodley; William R Mac Kenzie; Marc Weiner; Helen McIlleron; Carl M J Kirkpatrick Journal: Antimicrob Agents Chemother Date: 2012-05-07 Impact factor: 5.191
Authors: Anthony J Garcia-Prats; Heather R Draper; Stephanie Thee; Kelly E Dooley; Helen M McIlleron; James A Seddon; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Antimicrob Agents Chemother Date: 2015-07-20 Impact factor: 5.191
Authors: Anthony J Garcia-Prats; H Simon Schaaf; Heather R Draper; Maria Garcia-Cremades; Jana Winckler; Lubbe Wiesner; Anneke C Hesseling; Rada M Savic Journal: PLoS Med Date: 2019-04-30 Impact factor: 11.069
Authors: Mercedes Yanes-Lane; Edgar Ortiz-Brizuela; Jonathon R Campbell; Andrea Benedetti; Gavin Churchyard; Olivia Oxlade; Dick Menzies Journal: PLoS Med Date: 2021-09-14 Impact factor: 11.613
Authors: Alexander W Kay; Helena Rabie; Elizabeth Maleche-Obimbo; Moorine Penninah Sekadde; Mark F Cotton; Anna M Mandalakas Journal: Pathogens Date: 2021-12-29
Authors: Patricia Moscibrodzki; Leslie A Enane; Graeme Hoddinott; Meredith B Brooks; Virginia Byron; Jennifer Furin; James A Seddon; Lily Meyersohn; Silvia S Chiang Journal: Pathogens Date: 2021-12-08